GUANGDONG HYBRIBIO BIOTECH CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.51 CNY | -2.98% |
|
+3.99% | -30.30% |
| 26/04 | Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 24/04 | Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company returns high margins, thereby supporting business profitability.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -30.30% | 597M | - | ||
| -1.29% | 12.64B | B+ | ||
| -0.47% | 8.37B | B- | ||
| +5.68% | 5.37B | B | ||
| +22.61% | 5.26B | C | ||
| -2.03% | 4.58B | C | ||
| -53.56% | 3.16B | D+ | ||
| +19.30% | 2.89B | - | - | |
| -8.42% | 2.22B | B- | ||
| -3.55% | 1.91B | D+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300639 Stock
- Ratings Guangdong Hybribio Biotech Co.,Ltd.